Cargando…

Clinical benefit of high dose IL-2 (HD IL-2) therapy: evidence for improved overall survival in patients with stable disease

Detalles Bibliográficos
Autores principales:	Hughes, Tasha, Iodice, Gail, Basu, Sanjib, Bines, Steven, Kaufman, Howard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990294/ http://dx.doi.org/10.1186/2051-1426-1-S1-P105

Ejemplares similares

The role of surgery following incomplete response to high-dose IL-2 (HD IL-2)
por: Hughes, Tasha, et al.
Publicado: (2013)

Stable disease after high dose interleukin-2 (HD IL-2) immunotherapy: observations on long term survival and clinical benefit of additional HD IL-2
por: Kaufman, Howard L, et al.
Publicado: (2014)

Overall survival of metastatic melanoma patients treated with HD IL-2 followed by immune checkpoint blockade of the CTLA-4 or the PD-1 pathways: analysis of data on the current use of HD IL-2
por: Wong, Michael KK, et al.
Publicado: (2015)

Durability of responses in patients with metastatic renal cell carcinoma treated with high dose interleukin-2 (HD IL-2)
por: Clark, Joseph I, et al.
Publicado: (2015)

A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma
por: Buchbinder, Elizabeth I., et al.
Publicado: (2016)

Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM(SM) registry
por: Fishman, M., et al.
Publicado: (2019)

Complete metastasectomy after high-dose interleukin-2 (HD IL-2) therapy for melanoma
por: Chu, Melinda, et al.
Publicado: (2015)

Combination immunotherapy with Interleukin-2 and CTLA-4 blockade decreases tumor growth and improves overall survival
por: Broucek, Joseph R, et al.
Publicado: (2013)

High-Dose Interleukin-2 (HD IL-2) Therapy Should Be Considered for Treatment of Patients with Melanoma Brain Metastases
por: Chu, Melinda B., et al.
Publicado: (2013)

High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute
por: Davar, Diwakar, et al.
Publicado: (2017)

Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition
por: Buchbinder, Elizabeth I., et al.
Publicado: (2019)

Targeting IFNGR/IL6R or downstream JAK1/JAK2 to control GvHD
por: Ashami, Kidist, et al.
Publicado: (2018)

Role of dose selection in successful interleukin-2 immunotherapy: solving the Goldilock’s Complex
por: Zloza, Andrew, et al.
Publicado: (2013)

High dose interleukin-2 registry, PROCLAIM™; higher center-specific IL-2 dose density correlates with higher response rates
por: Wong, Michael K, et al.
Publicado: (2013)

The IL-17A/IL-17RA Axis Is Not Related to Overall Survival and Cancer Stem Cell Modulation in Pancreatic Cancer
por: Li, Jiahui, et al.
Publicado: (2020)

IL-6 and IL-8 Serum Levels Predict Tumor Response and Overall Survival after TACE for Primary and Secondary Hepatic Malignancies
por: Loosen, Sven H., et al.
Publicado: (2018)

Pretreatment Serum Levels of IL-1 Receptor Antagonist and IL-4 Are Predictors of Overall Survival in Multiple Myeloma Patients Treated with Bortezomib
por: Mikulski, Damian, et al.
Publicado: (2021)

IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma
por: Xu, C-F, et al.
Publicado: (2015)

Low-dose IL-2 enhances the generation of IL-10-producing immunoregulatory B cells
por: Inaba, Akimichi, et al.
Publicado: (2023)

Open-label, randomized, multi-center study comparing the sequence of high dose Aldesleukin (Proleukin(® )(HD IL-2) and Ipilimumab Yervoy(® )) in patients with metastatic melanoma (proclivity 02)
por: Patel, Sapna, et al.
Publicado: (2014)

Simvastatin Suppresses Airway IL-17 and Upregulates IL-10 in Patients With Stable COPD
por: Maneechotesuwan, Kittipong, et al.
Publicado: (2015)

Blimp-1 directly represses Il2 and the Il2 activator Fos, attenuating T cell proliferation and survival
por: Martins, Gislâine A., et al.
Publicado: (2008)

Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma
por: Kaufman, Howard L, et al.
Publicado: (2009)

In vivo stimulation of IL-12 secretion by subcutaneous low-dose IL-2 in metastatic cancer patients.
por: Lissoni, P., et al.
Publicado: (1998)

Changes in IL-16 Expression in the Ovary during Aging and Its Potential Consequences to Ovarian Pathology
por: Ramirez, Jessica, et al.
Publicado: (2022)

Data on interleukin (IL)-2- and IL-15-dependent changes in IL-2Rβ and IL-2Rγ complexes
por: Osinalde, Nerea, et al.
Publicado: (2017)

The Impact of IL-6 and IL-10 Gene Polymorphisms in Diffuse Large B-Cell Lymphoma Risk and Overall Survival in an Arab Population: A Case-Control Study
por: Al-Khatib, Sohaib M., et al.
Publicado: (2020)

Quantitative Contribution of IL2Rγ to the Dynamic Formation of IL2-IL2R Complexes
por: Ponce, Luis F., et al.
Publicado: (2016)

Prolonged continuous infusion of low-dose rIL-2.
por: Janssen, R. A., et al.
Publicado: (1994)

Low-Dose IL-2 Therapy in Autoimmune and Rheumatic Diseases
por: Graßhoff, Hanna, et al.
Publicado: (2021)

Pretreatment Plasma IL-6 and YKL-40 and Overall Survival after Surgery for Metastatic Bone Disease of the Extremities
por: Sørensen, Michala Skovlund, et al.
Publicado: (2021)

NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade
por: Kohlhapp, Frederick J, et al.
Publicado: (2015)

IL-10 mRNA Engineered MSCs Demonstrate Enhanced Anti-Inflammation in an Acute GvHD Model
por: Zhang, Cuiping, et al.
Publicado: (2021)

High-dose interleukin-2 (hd-IL2) in treatment-naïve metastatic renal cell carcinoma (mrcc) - a 10 year single-site experience and outcome of prospective pathology-based patient selection
por: Chow, Shien, et al.
Publicado: (2014)

A multi-center study of high dose Aldesleukin (Proleukin(® )(HD IL-2) + Vemurafenib Zelboraf(® )) therapy in patients with BRAF(V600 )mutation positive metastatic melanoma (proclivity 01)
por: Clark, Joseph, et al.
Publicado: (2014)

Genetic characterization of interleukins (IL-1α, IL-1β, IL-2, IL-4, IL-8, IL-10, IL-12A, IL-12B, IL-15 and IL-18) with relevant biological roles in lagomorphs
por: Neves, Fabiana, et al.
Publicado: (2015)

High-Dose IL-2 Skews a Glucocorticoid-Driven IL-17(+)IL-10(+) Memory CD4(+) T Cell Response towards a Single IL-10–Producing Phenotype
por: Mann, Elizabeth H., et al.
Publicado: (2019)

Targeting IL-6 Trans-Signaling: Amplifying the Benefits of IL-6 Inhibition in Myocardial Infarction
por: Aukrust, Pål, et al.
Publicado: (2021)

Evaluation of the IL2/IL21, IL2RA and IL2RB genetic variants influence on the endogenous non-anterior uveitis genetic predisposition
por: Cénit, María Carmen, et al.
Publicado: (2013)

IL-2 coordinates IL-2–producing and regulatory T cell interplay
por: Amado, Inês F., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_e1d7v7eip1ip79f18m7cfimmjc